Initial One-Year Exclusivity Period Will Be Extended to Three Years if Endari is Approved for Marketing TORRANCE, Calif., Jan. 29, 2025 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.